Page 1

A Brisardik Pharmaceuticals Product Presentation by: David Brinser, Tiana Harris and Michele Hladik


About Brisardik  Established in 1987  Based in Columbus, Ohio  More than 500 physicians, chemists, and lab assistants  Known for popular ADHD medications and anti depressants  Creator of Intelliboost


Intelliboost  Taken once daily  Prescription  Gradually builds up  Strengthen and develops decision making and processing functions  Could be sold in a variety of sizes

 Study to determine if medication works and is ready for sale


Study Participants  Randomly selected 60 adults  Customers and research volunteers  Intelligence testing  30 given Intelliboost, 30 placebos  Intelligence retesting


Data Collection  Participant IDs  Test scores recorded  Data sorted in several ways including:

     

All participants Intelliboost recipients Placebo recipients Gender Age Improvements made


Patients Taking Intelliboost Participant ID. Before 1001 140 1002 110 1006 138 1007 141 1010 70 1011 119 1014 113 1015 78 1018 143 1019 125 1022 86 1023 126 1026 76 1027 127 1030 92

Average

Participant ID. Before 1031 117 1034 95 1035 147 1037 96 1043 74 1045 97 1046 129 1047 149 1048 94 1050 130 1051 99 1054 95 1055 112 1057 114 1060 96

After 143 110 135 142 74 122 125 78 144 130 87 127 80 128 95

Before 110.9333

After 114.3333

After 117 96 148 105 74 105 135 149 105 128 110 100 112 120 106


Patients Taking Placebo Participant ID. 1003 1004 1005 1008 1009 1012 1013 1016 1017 1020 1021 1024 1025 1028 1029

Before 80 97 92 90 123 142 77 134 99 81 91 144 112 98 145

Average

Participant ID. 1032 1033 1036 1038 1040 1041 1044 1042 1039 1049 1052 1053 1056 1058 1059

After 82 103 92 95 123 138 77 132 100 85 93 142 112 98 145

Before 104.4

After 104.9333

Before 84 71 79 135 116 148 110 89 93 85 111 120 90 75 121

After 84 72 79 130 116 148 112 89 93 86 111 121 94 75 121


Data by Age Intelliboost Placebo

18-27 6 5

Increased IQ with Intelliboost January March 18-27 3 1 28-37 4 2 38-47 5 3 48-57 4 1 58 & Older 1 0

28-37 9 8

38-47 8 9

48-57 5 6

Increased IQ with Placebo January 18-27 2 28-37 4 38-47 4 48-57 2 58 & Older 0

58 and older 2 2

March 1 2 2 1 0


Summary Output All Data  The independent variable

medicine/placebo

 The dependent variable

the IQ score

 Scatter diagram All Participants Before/After 160 140

120

After

100 80 60 40 20 0

0

20

40

60

80 Before

100

120

140

160


Linear Correlation All Data  Coefficient of correlation-r=0.9911

r = 0.991146 p = 0.000000

 Strong positive correlation  Represents a good model  The line fits the points well  r suggests there is a linear correlation between IQ scores and the use of a placebo or new medication

y=a+bx a=7.663276883 b=.9473999051 n=60 7.663276883+.94739990 51(60)=64.5073 slope = 1.03691245


All Data Continued…  A few outliers based on the scatter diagram are (94,105), (96,106), (97,103), (75,75), and (129, 135)  Using (129,135) and entering it into the regression line the solution would be: 7.6633+.9474(129)=130  This predicted answer is close to the observed answer of 135.  This is not too far beyond the scope of available data.  The point with the largest residual is (94,105).  7.6633+.9474(94)=97  105-97=8 equaling the largest residual. This point does not accurately represent the regression line.


Summary Output-Intelliboost  The independent variable

the medicine

 The dependent variable

the IQ score

 Scatter diagram Patients Taking Intelliboost 160 140

After

120 100 80

Series1

60

Linear (Series1)

40 20 0 0

50

100 Before

150

200


Correlation - Intelliboost  Coefficient of correlation r=.9847  Strong positive correlation  This represents a good model  The line fits the points well  r suggests there is a linear correlation between IQ scores and the use of the new medication

slope=1.02528284 5 p=0.0000 r=0.9847 r square=0.9696 y=a+bx a=9.4258 b=0.9457 n=30 9.4258+.9457x


Intelliboost Continued…  A few outliers based on the scatter diagram are (113,125) and (99,110).

 Using point (140,143) and entering it into the regression line: y=9.4258+0.9457(140)=142 with a residual of 1.  The predicted answer is close to the observed answer of 143. This is not too far beyond the scope of available data.  97% of participants saw a change in their IQ after taking the new medicine  y=9.4258+.9457(99)=103 with a residual difference of 7.  y=9.4258+.9457(113)=116 with a residual difference of 9.  This point has the largest residual value and does not accurately represent the regression line.


Summary Output-Placebo  The independent variable

the placebo

 The dependent variable

the IQ score

 Scatter diagram

Patients Taking New Placebo 160 140

After

120 100 80

Series1

60

Linear (Series1)

40 20 0 0

50

100 Before

150

200


Correlation - Placebo  Coefficient of correlation r=0.9963  Strong positive correlation  This represents a good model  The line fits the points well  r suggests there is a linear correlation between the IQ scores and the use of the placebo

slope=1.04585667 p=0.0000 r=0.9963 r square=0.9926 y=a+bx a=5.8513 b=0.9491 n=30 5.8513+0.9491


Placebo Continued…  There are no outliers on the placebo scatter diagram

 Using point (80,82) and entering it into the regression line: y=5.8513+0.9491(80)=82  It has a residual of 0.  The predicted answer is exactly the same as the observed answer of 82. This is exactly within the scope of available data.  Using the point (97,103) and entering it into the regression line: y=5.8513+.9491(97)=98 with a residual of 5.

 This point has the largest residual value and does not accurately represent the regression line.


ANOVA  Test criteria  Test results  Importance of the mean

Intelliboost ANOVA f= .33425 p=.5654

Placebo ANOVA f=.00809 p=.9286


Paired Test  Breakdown of test

Intelliboost Paired Test

Placebo Paired Test

 Analyzing results

t= 4.55279 p=.00004387 x= 3.4 Sx=4.09035 n=30

t= 1.2867 p= .10418 x= -.5333 Sx= 2.2702 n= 30

 Validity of test

Critical value for 29 deg of freedom is : 2.045


Final Recommendations  Move forward with Intelliboost.  Seek final approval from the United States Food and Drug Administration

 Begin marketing Intelliboost  Begin production and pharmaceutical distribution of Intelliboost


Closing  Thank you!  Questions


Footnote Note: Brisardik Pharmaceuticals and Intelliboost were invented for the sake of this project. All data was created for the project purposes only. Data collection methods are designed to show how the data would have been collected if the company, drug and study were real.

Intelliboost  

A study of a new drug designed to boost intelligence.

Read more
Read more
Similar to
Popular now
Just for you